Abstract
We report herein a series of substituted N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure-activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models.
MeSH terms
-
Angiogenesis Inhibitors / chemical synthesis
-
Angiogenesis Inhibitors / pharmacology*
-
Animals
-
Cell Line
-
Cytochrome P-450 CYP3A Inhibitors
-
Drug Design*
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels / antagonists & inhibitors
-
Humans
-
Inhibitory Concentration 50
-
Mice
-
Mice, Inbred BALB C
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Pyrroles / chemical synthesis
-
Pyrroles / pharmacology*
-
Structure-Activity Relationship
-
Triazines / chemical synthesis
-
Triazines / pharmacology*
-
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*
-
Xenograft Model Antitumor Assays
Substances
-
5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo(2,3-b)pyridin-5-yl)pyrrolo(2,1-f)(1,2,4)triazin-4-amine
-
Angiogenesis Inhibitors
-
Cytochrome P-450 CYP3A Inhibitors
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels
-
Pyrroles
-
Triazines
-
Protein-Tyrosine Kinases
-
Vascular Endothelial Growth Factor Receptor-2